ID: h-var-12f509effb
Hypothesis

LXRβ-Selective Agonism Enhances CYP2J2-Mediated DHA Epoxide Generation to Restore Synaptic Membrane Homeostasis in Alzheimer's Disease

This hypothesis proposes that LXRβ-selective agonists enhance CYP2J2 expression and activity to increase protective DHA epoxide generation, simultaneously addressing both cholesterol dysregulation and membrane rigidification in Alzheimer.
🧬 NR1H2 (LXRβ)🩺 lipidomics🎯 Composite 38%💱 $0.48▲21.5%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 5 support 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.80 (15%) Evidence 0.34 (15%) Novelty 0.00 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.80 (10%) Safety 0.70 (8%) Competition 0.55 (6%) Data Avail. 0.75 (5%) Reproducible 0.75 (5%) KG Connect 0.50 (8%) 0.380 composite

🧪 Overview

This hypothesis proposes that LXRβ-selective agonists enhance CYP2J2 expression and activity to increase protective DHA epoxide generation, simultaneously addressing both cholesterol dysregulation and membrane rigidification in Alzheimer's disease. LXR signaling is known to upregulate cytochrome P450 enzymes involved in lipid metabolism, including CYP2J2, through direct transcriptional control. By selectively activating LXRβ, this approach would increase endogenous CYP2J2-mediated conversion of DHA to protective epoxides that prevent Aβ-induced synaptic membrane rigidification, while concurrently promoting cholesterol efflux from activated microglia and enhancing APOE lipidation. This dual mechanism addresses the critical pathophysiology where Aβ oligomers increase membrane cholesterol content by ~40% and expand raft domains in cortical neurons. The LXRβ-mediated upregulation of CYP2J2 would provide a sustainable source of protective epoxides, potentially overcoming the pharmacokinetic limitations of direct DHA supplementation where epoxides have 2-4 hour half-lives due to rapid sEH metabolism.

...

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["DHA Substrate Pool<br/>Membrane Omega-3 Lipids"]
    B["CYP2J2 Epoxygenase<br/>DHA-to-Epoxide Conversion"]
    C["Epoxy-DHA Mediators<br/>Anti-inflammatory Lipid Signals"]
    D["sEH Inhibition<br/>Epoxide Lifetime Prolonged"]
    E["Synaptic Membrane Fluidity<br/>A-beta-Induced Rigidification Blocked"]
    F["Excitatory Signaling Stability<br/>Receptor Mobility Preserved"]
    G["Synaptic Protection<br/>Reduced A-beta Toxicity"]
    A --> B
    B --> C
    D --> C
    C --> E
    E --> F
    F --> G
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style D fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
    style G fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix5 supports3 contradicts
Supports
CYP2J2-derived epoxides protect against Aβ-induced membrane rigidity in planar lipid bilayer experiments
Supports
DHA supplementation in 5xFAD mice reduces Aβ burden and improves synaptic plasticity markers
Supports
Soluble Aβ oligomers increase membrane cholesterol by 40% and raft domain size in cortical neurons
Supports
EC-5026 (sEH-397) Phase I completed, FDA IND cleared 2019 for pain indication
EicOsis/UC Davis clinical registry
Supports
GSK225629 Phase I completed for COPD/pain with CNS penetration demonstrated
GlaxoSmithKline clinical registry
Contradicts
Epoxides are rapidly metabolized by soluble epoxide hydrolase (sEH), with half-lives of 2-4 hours in plasma
Contradicts
The membrane fluidity model was tested in artificial planar bilayers, not neuronal membranes
Skeptic critique
Contradicts
DHA supplementation activates multiple pathways (resolvins, protectins, maresins)—benefits cannot be attributed specifically to CYP2J2 epoxides
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — NR1H2

No curated PDB or AlphaFold mapping for NR1H2 yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for NR1H2 (LXRβ) →

No DepMap CRISPR Chronos data found for NR1H2 (LXRβ).

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.3%
Volatility
Low
0.0200
Events (7d)
2
Price History
▲21.5%

💾 Resource Usage

LLM Tokens
38,938
$0.1168
Total Cost
$0.1168
Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
sourcev1_phase_c_backfill
origin_typegap_debate
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.